Leukemia
ASH 2022: Zanubrutinib in Patients With Relapsed or Refractory CLL/SLL
You're currently viewing OncGenius as a guest. To save your results, create an account or log in.
Advertisement
ASH 2022: Zanubrutinib in Patients With Relapsed or Refractory CLL/SLL
ASH 2022: Efficacy of Triplet Combinations in Acute Myeloid Leukemia
Safety and Efficacy of Sotorasib in KRAS-Mutated Pancreatic Cancer
ASH 2022: Impact of Momelotinib on Patient-Reported Quality of Life for Patients With Myelofibrosis
ASH 2022: Talquetamab for Relapsed or Refractory Multiple Myeloma
Risk of ALCL Following Postmastectomy Implant Reconstruction
SABCS 2022: First-Line Ribociclib Plus Endocrine Therapy in Patients With Aggressive Breast Cancer
ASH 2022: Re-evaluating the Standard of Care in Mantle Cell Lymphoma
Patients With Multiple Myeloma Receiving Salvage Treatment After BCMA-Directed CAR T-Cell Therapy
Integrative Approaches to Managing Pain in Patients With Cancer: SIO/ASCO Guideline
Subset of Patients With a Very Low Risk of Dying From Melanoma
NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas (Version 3.2022)
Real-World Cost of Pediatric ALL Care Among Commercially Insured Patients
ASTRO 2022: A Novel Approach for Radiotherapy in Orbital Indolent B-Cell Lymphoma
ESMO 2022: Pembrolizumab and Chemoradiation for Locally Advanced Head and Neck Cancer
Radiopharmaceuticals for Treatment of Metastatic Castration-Resistant Prostate Cancer
Physician Survey: Breast Cancer Screening Among Transgender Patients
Anaplastic Large-Cell Lymphoma of the Breast: Incidence in the United States
ESMO 2022: COSMIC-313 Trial of Triplet Therapy in Advanced Renal Cell Carcinoma
Trends in Improvements in Survival Among Patients With DLBCL
Consumption of Ultraprocessed Foods and Colorectal Cancer Risk
ESMO 2022: Air Pollution and Non–Small Cell Lung Cancer Risk
ESMO 2022: SWOG S1801 Trial of Timing of Pembrolizumab in Resected Advanced Melanoma
Trends in Cutaneous T-Cell Lymphoma Incidence in the United States
Diet Quality and Survival Among Patients With Head and Neck Cancer
UV-Protective Behaviors Among American Indians and Alaskan Natives
Germline Testing for Patients With Lung Cancer: ASCO Plenary Series
Older Patients With Advanced Bladder Cancer: Care Planning Priorities
Dosing of Tisagenlecleucel Among Pediatric Patients With Leukemia and Improved Outcomes
Acute Leukemia Survival Outcomes Over Time in South Australia
Real-World Outcomes With Axicabtagene Ciloleucel Therapy for Large B-Cell Lymphoma
Multiple Myeloma: Caregiver Quality of Life and Psychological Distress
Phase III Trial Evaluates Quizartinib for FLT3-ITD–Positive AML
Zanubrutinib for Untreated Patients With CLL/SLL: SEQUOIA Trial
Rapid Recommendation Update to ASCO Guideline for Systemic Treatment of Melanoma
Trends in the Use of Medical Aid in Dying in the United States
ASCO 2022: Asciminib vs Bosutinib in Pretreated Patients With CML in Chronic Phase
Characteristics of Advanced Extranodal Natural Killer/ T-Cell Lymphoma and its Treatment
Results From Large Real-World Cohorts on Treatment Outcomes in Patients With Mantle Cell Lymphoma
Consumption of Sugar-Sweetened Beverages and Risk of Liver Cancer
ASCO 2022: Real-World Data on Maintenance Olaparib in BRCA-Mutated Ovarian Cancer
ASCO 2022: Crenolanib Combined With Chemotherapy in Newly Diagnosed FLT3-Mutant AML
ASCO 2022: Dostarlimab-gxly in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
ASCO 2022: Nimotuzumab Plus Gemcitabine for KRAS Wild-Type Pancreatic Cancer
ASCO 2022: New Data on IDH2-Mutant Alleles and Endasidenib in AML
The Financial Burden of Thyroid Cancer Care in the United States
ASCO 2022: Sacituzumab Govitecan-hziy for HR-Positive/HER2-Negative Advanced Breast Cancer
ASCO 2022: Measurable Residual Disease Testing as Prognostic Tool in Acute Myeloid Leukemia
ASCO 2022: Adding ASCT to Triplet/Maintenance Therapy for Newly Diagnosed Multiple Myeloma
ASCO 2022: Panitumumab Plus mFOLFOX6 for Certain Patients With Metastatic Colorectal Cancer
ASCO 2022: T-DXd in HER2-Low Unresectable and/or Metastatic Breast Cancer
ASCO 2022: Using ctDNA to Guide Adjuvant Chemotherapy in Colon Cancer
ASCO 2022: Ibrutinib Added to Bendamustine/Rituximab for Older Patients With Mantle Cell Lymphoma
ASCO 2022: State Public Welfare Spending and Disparities in Overall Survival
ASCO 2022: Disparities in Telemedicine Use for Patients With Cancer During the COVID-19 Pandemic
ASCO 2022: Black Patient Participation in Clinical Trials for Metastatic Breast Cancer
NCCN Guidelines for Non–Small Cell Lung Cancer (Version 3.2022)
CAR T-Cell Therapy: Rates of Rehospitalization and Emergency Department Visits Postinfusion
Addition of Ivosidenib to Azacitidine in Newly Diagnosed IDH1-Mutated AML
Total Burden of Psychiatric Disorders Across All Common Adult Cancers
Innate Cell Engager AFM13 Plus Natural Killer Cells for Lymphoma
MSI-H/dMMR Advanced Colorectal Cancer: Pembrolizumab vs Chemotherapy
Tislelizumab Plus Chemotherapy for Recurrent/Metastatic Nasopharyngeal Cancer: RATIONALE-309
CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC
NCCN Guidelines for the Management of Immunotherapy-Related Toxicities (Version 1.2022)
Rucaparib vs Standard-of-Care Chemotherapy for BRCA1/2-Mutated, Relapsed Ovarian Cancer
Immune Responses Among Patients With B-Cell Malignancies Post–COVID-19 Vaccination
Combined BCMA and CD19 CAR T-Cells in Relapsed or Refractory Multiple Myeloma
Pembrolizumab/Trametinib vs Gemcitabine in Addition to SBRT for Pancreatic Cancer
Immunotherapy Doublet in Patients With MSI-H/dMMR Metastatic Colorectal Cancer
Strategy for De-Escalating Radiation Therapy for Patients With Oropharyngeal Cancer
Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer
Communication Skills Challenges for Advanced Practice Providers
Outcomes of Patients With an Ultra-Low–Risk 70-Gene Signature in the MINDACT Trial
Polatuzumab Vedotin-piiq Plus R-CHP vs R-CHOP in Previously Untreated DLBCL: POLARIX Trial
Combination Anti–PD-L1 and Anti–CTLA-4 Immunotherapy in Advanced Liver Cancer
Cancer During COVID-19: Resilience of Patients With Lung Cancer
Using PET Scans to Direct Therapy Decisions in Advanced Hodgkin Lymphoma
AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care
Mosunetuzumab for Relapsed or Refractory Aggressive and Indolent B-Cell Non-Hodgkin Lymphomas
TOPAZ-1 Trial: Durvalumab and Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Treatment Options for Patients With GIST Following Disease Progression
Managing Breakthrough Cancer Pain: Role of Shared Decision-Making
Tebentafusp-tebn for the Treatment of Unresectable or Metastatic Uveal Melanoma
T-DXd in Previously Treated Patients With Metastatic HER2-Mutant NSCLC
Case-Control Study of Risk of Cardiometabolic Risk Factors in Breast Cancer Survivors
BNT162b2 COVID-19 Vaccination and Immune Response in Patients Undergoing Anticancer Treatment
Dual Checkpoint Inhibition for Second-Line Treatment of Advanced Cervical Cancer
Emerging Therapies and Current Unmet Needs for Patients With Relapsed or Refractory DLBCL
Relatlimab and Nivolumab vs Nivolumab Alone in Untreated Advanced Melanoma
Treatment-Related Regret Among Men With Localized Prostate Cancer: Examining Potential Factors
COVID-19 Vaccination and SARS–CoV-2 Infection Among Patients With Cancer